-transparent.png){kind=logo}
Transforming growth factor-beta is known to be a potent autocrine growth inhibitor produced by a wide variety of cells, including cells of the immune system. Other investigators have noted that the growth of nontransformed keratinocytes is inhibited by transforming growth factor-beta, whereas various carcinoma cell lines are resistant to these effects. Head and neck squamous cell carcinoma cells are known to have surface receptors for this cytokine. We thus assessed the effect of transforming growth factor-beta on the growth of head and neck squamous cell carcinoma cell lines. Four head and neck squamous cell carcinoma cell lines were incubated with varying concentrations of transforming growth factor-beta, and cytotoxicity was evaluated with a methylene blue colorimetric assay. After culturing in transforming growth factor-beta for 4 days, inhibition of growth was detected in CAL-27 (maximal inhibition at 5.0 ng/ml), UMSCC-1, and UMSCC-19 (maximal inhibition at 50 ng/ml) cell lines. One other cell line, UMSCC-8 was found resistant to the inhibitory effects of transforming growth factor-beta. Kinetics analysis experiments revealed minimal inhibition before day 2 of incubation, at which time inhibition increased linearly to day 4. Assessment of double-stranded DNA fragmentation suggested that DNA fragmentation occurs before significant cytotoxicity. Electron microscopic analysis and gel electrophoresis of extracted DNA revealed morphologic features consistent with apoptotic cell death. Our findings indicate that transforming growth factor-beta significantly inhibits the growth of head and neck squamous cell carcinoma cell lines by inducing apoptotic cell death.
K B Briskin, and
C Fady, and
R A Mickel, and
M Wang, and
A Lichtenstein
July 1996,
The Laryngoscope,
K B Briskin, and
C Fady, and
R A Mickel, and
M Wang, and
A Lichtenstein
June 1999,
Clinical cancer research : an official journal of the American Association for Cancer Research,
K B Briskin, and
C Fady, and
R A Mickel, and
M Wang, and
A Lichtenstein
January 2009,
International journal of otolaryngology,
K B Briskin, and
C Fady, and
R A Mickel, and
M Wang, and
A Lichtenstein
December 1996,
American journal of surgery,
K B Briskin, and
C Fady, and
R A Mickel, and
M Wang, and
A Lichtenstein
May 2006,
Genes & development,
K B Briskin, and
C Fady, and
R A Mickel, and
M Wang, and
A Lichtenstein
September 2012,
Acta oto-laryngologica,
K B Briskin, and
C Fady, and
R A Mickel, and
M Wang, and
A Lichtenstein
December 2009,
Cancer research,
K B Briskin, and
C Fady, and
R A Mickel, and
M Wang, and
A Lichtenstein
October 1992,
Genes, chromosomes & cancer,
K B Briskin, and
C Fady, and
R A Mickel, and
M Wang, and
A Lichtenstein
January 2001,
In vitro cellular & developmental biology. Animal,
K B Briskin, and
C Fady, and
R A Mickel, and
M Wang, and
A Lichtenstein
December 2015,
Hematology/oncology clinics of North America,
